TABLE 2

Diagnostic potential of mutations at known resistance-conferring locia

DrugGeneMutationFrequencyPPVSensitivitySpecificity
RifampinAny 7010.991
rpoB D435Yb,c210.031
H445D/L/Yb,c1910.271
S450L/Wb,c4910.691
IsoniazidAny 720.990.970.96
katG S315Tc7110.971
inhA c-15tc260.960.340.96
t-8a/cc2610.361
OfloxacinAny 4310.911
gyrA A90Vc1410.281
S91Pc410.081
D94A/G/H/N/Yc2510.501
gyrB D461N210.041
N499T110.021
KanamycinAny 400.900.730.91
rrs a1400gc3110.611
c1483tc110.021
eis g-10a2000.96
c-14t60.670.080.96
AmikacinAny 3210.861
rrs a1400gc3110791
c1483tc110.031
CapreomycinAny 350.970.830.98
rrs a1400gc3110.721
c1483tc110.021
tlyA LOF30.670.050.98
StreptomycinAny 7010.931
rpsL K43R4110.551
K88R310.041
rrs a513c1910.251
a516t610.081
gidB LOF210.031
PyrazinamideAny 310.161
pncA LOF310.161
EthambutolAny 630.980.900.96
embB M306I/Vc380.970.530.96
G406D110.011
Q497R2410.341
EthionamideAny 650.3510.42
ethA LOF470.360.740.59
inhA c-15tc260.500.570.82
t-8a/cc260.230.260.73
  • a Isolates were included only if they had both phenotypic and genotypic resistance predictions. For each mutation, we show frequency of the mutation in the data set, positive predictive value (PPV), sensitivity, and specificity for predicting phenotypic resistance. Mutations are listed as either specific changes or as any loss-of-function (LOF) mutation, including nonsense mutations and frameshifts.

  • b Mutation detectable by GeneXpert MTB/RIF.

  • c Mutation detectable by MTBDRplus version 2.0 or MTBDRsl version 1.0.